POST MARKETING STUDY OF THE ELIXIR DESyne NOVOLIMUS ELUTING CORONARY STENT SYSTEM AND THE DESyne BD NOVOLIMUS ELUTING CORONARY STENT SYSTEM IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS
Phase of Trial: Phase IV
Latest Information Update: 05 Feb 2018
Price : $35 *
At a glance
- Drugs Novolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms EXCELLA PMCF
- Sponsors Elixir Medical Corporation
- 30 Jan 2018 Status changed from active, no longer recruiting to completed.
- 07 Feb 2017 Planned End Date changed from 1 Mar 2017 to 1 Jun 2017.
- 07 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2017.